Weekly Research Analysts’ Ratings Updates for AbbVie (ABBV)

A number of research firms have changed their ratings and price targets for AbbVie (NYSE: ABBV):

• 5/17/2026 – AbbVie was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 5/15/2026 – AbbVie was given a new $235.00 price target by Evercore Inc.
• 5/14/2026 – AbbVie had its price target raised by Piper Sandler from $294.00 to $298.00. They now have an “overweight” rating on the stock.
• 5/9/2026 – AbbVie was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 5/1/2026 – AbbVie had its “buy” rating reaffirmed by Guggenheim. They now have a $249.00 price target on the stock.
• 4/30/2026 – AbbVie was upgraded by DZ Bank AG from “hold” to “strong-buy”.
• 4/30/2026 – AbbVie had its price target raised by Canaccord Genuity Group Inc. from $262.00 to $265.00. They now have a “buy” rating on the stock.
• 4/30/2026 – AbbVie had its price target raised by Morgan Stanley from $270.00 to $278.00. They now have an “overweight” rating on the stock.
• 4/30/2026 – AbbVie had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $240.00 price target on the stock.
• 4/30/2026 – AbbVie was upgraded by Bank of America Corporation from “neutral” to “buy”. They now have a $234.00 price target on the stock.
• 4/23/2026 – AbbVie had its price target lowered by Piper Sandler from $299.00 to $294.00. They now have an “overweight” rating on the stock.
• 4/20/2026 – AbbVie is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $262.00 price target on the stock.
• 4/20/2026 – AbbVie was upgraded by Canaccord Genuity Group Inc. to “strong-buy”.
• 4/11/2026 – AbbVie was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 4/10/2026 – AbbVie had its price target raised by Guggenheim from $242.00 to $249.00. They now have a “buy” rating on the stock.
• 4/8/2026 – AbbVie had its price target lowered by Cantor Fitzgerald from $250.00 to $240.00. They now have an “overweight” rating on the stock.

Insider Buying and Selling at AbbVie

In other news, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.06% of the company’s stock.

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.